Form D · Biotechnology

ANAVEX LIFE SCIENCES CORP.

New York, NY · CIK 0001314052

Offering snapshot reported Apr 2, 2014 · SEC filing

Reported sold
$10M
Offering amount: $10M
Investors reported
11
Form D · investor count
Minimum accepted
$107K
Reported outside-investor minimum
First sale
Mar 18, 2014
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 2, 2014Initial$10,000,000No comparison11SEC filing
Feb 16, 2012Initial$10,000No comparison1SEC filing
Nov 26, 2010Initial$49,500No comparison1SEC filing
Jul 6, 2010Initial$500,000No comparison1SEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$700K
Finders' fees
$0
Form D file number
021-214701

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Maxim Group LLC120708

Source: Form D, filed Apr 2, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Alison Ayers Director
John Chisholm Director
Cameron Durrant Director
Harvey Lalach Director, Executive
Sean Lowry Director
Christopher U. Missling Director, Executive
Athanosios Skarpelos Director
George Tidmarsh Director, Executive
David Tousley Director
Alexandre Vamvakides Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
51 W 52 Nd Street 7 Th Floor
New York, NY, 10019